New HIV prevention injection Lenacapavir arrives in South Africa

The Department of Health has welcomed the arrival of the first batch of HIV prevention medicine, Lenacapavir, in the country.

The initial consignment, comprising roughly 37 920 doses, was delivered last week.

In a statement issued on Tuesday, April 7, the department said the drug forms part of integrated, differentiated and people-centred HIV prevention services, offering new hope to those who face barriers to existing methods.

ALSO READ: Local hospital tackles HIV treatment gaps with new virological failure clinic

“Lenacapavir will boost the country’s efforts to reduce new HIV infections, helping to end Aids as a public health threat by 2030 and sustain the HIV response beyond 2030, in line with the Global Aids Strategy for 2026–2030,” the department said.

The official launch date is expected to be announced soon, along with a phased implementation plan.

The department described Lenacapavir as a six-monthly injectable expected to expand prevention options and improve adherence, particularly among vulnerable groups, including adolescent girls and young women, sex workers, and men who have sex with men.

“Lenacapavir is a preventive medicine, not a vaccine, and is considered one of the most exciting HIV prevention advances in years.

“The Minister of Health, Dr Aaron Motsoaledi, is very excited about this development and will, in consultation with the President, announce the launch date,” the statement concluded.